Will AVTR's FY2026 adjusted EPS exceed the high end of guidance ($0.83)?

FY2026 adj. EPS guidance is $0.77-$0.83. Beating the high end ($0.83) requires EPS above what was already the optimistic end of management own range. The 2025 pattern of progressive guidance cuts resulted in actual EPS of $0.90 — within the final narrowed range but below original expectations. New management may have set a beatable bar (kitchen-sink scenario), but the guided margin compression (100-150bps), continued revenue decline (-2.5% to -0.5%), and 685M diluted shares all work against exceeding $0.83. The cost savings of $265M run-rate provide a floor but are being absorbed by competitive pricing pressure. For EPS to exceed $0.83, revenue would need to come in at the high end of guidance or better, margins would need to compress less than guided, or both.

The classic turnaround playbook is to kitchen-sink Year 1 guidance and beat it. Ligner has the background (Danaher/Cytiva) and incentives ($993K personal purchase, massive equity grants) to execute this playbook. The $0.83 high end may have been set to be achievable. However, the 2025 experience shows that even seemingly conservative guidance can prove optimistic when competitive dynamics deteriorate. The question is whether 2026 is genuinely a kitchen-sink or whether the challenges (VWR structural decline, margin compression, bioprocessing bottlenecks) make even the low end ($0.77) achievable. I give 38% — the turnaround playbook is real but execution risk is high.

The self-funding contradiction is important. If Revival investments are truly self-funded from cost savings, the net EPS impact should be neutral. Yet guidance implies significant EPS decline ($0.90 to $0.77-$0.83). This suggests either: (1) the investments are not self-funded and create incremental costs, or (2) the operational deterioration is worse than the turnaround benefits. Either interpretation makes beating the high end of guidance difficult. The back-half weighted nature of FCF and EPS guidance means H2 needs to be materially better than H1, which requires visible improvement from Revival by mid-year. At 33%, I reflect genuine execution risk.

Beating the high end of guidance ($0.83) when the guide already represents a 10-14% decline from FY2025 is asking for the best-case scenario within an already deteriorating trajectory. Revenue declines of 2.5% to 0.5% and margin compression of 100-150bps create fundamental headwinds. The $265M cost savings are real but insufficient to overcome these headwinds. Unless revenue surprises meaningfully to the upside or margin compression is much less than guided, $0.83+ is unlikely.

New management guidance cycles are notoriously conservative in Year 1. Ligner has every incentive to set a beatable bar — his equity grants vest in Feb 2027+ and are tied to stock performance. If he can deliver $0.85-0.87 against $0.83 guidance, it would establish credibility and potentially drive a re-rating. The $100M in new pharma wins and bioprocessing demand strength provide upside pathways. However, the VWR distribution headwinds are the dominant force at 72% of revenue. I give 35% — kitchen-sink is plausible but VWR headwinds may overwhelm.

The question specifically asks about exceeding the high end ($0.83), not just beating consensus. Companies typically manage guidance to achieve results within the range, not above it — beating the high end would mean the range was miscalibrated. New management usually sets a beatable low end rather than a beatable high end. The most likely outcome is EPS of $0.80-$0.84, right at the high end — management will probably guide up slightly through the year. But exceeding $0.83 is a stretch given the structural challenges.

FY2026 guide of $0.77-$0.83 already represents significant decline from $0.90. Beating the high end requires best-case execution across revenue, margins, and costs. VWR structural headwinds and margin compression make this unlikely. 30% probability.

The 2025 pattern of guide-and-miss is the dominant consideration. Even after progressive guidance cuts, the prior management team barely met lowered expectations. The new team may be different but the competitive dynamics (Thermo Fisher pressure) and structural issues (VWR distribution) have not changed. Revenue decline and margin compression create fundamental EPS headwinds that cost savings alone cannot overcome.

Kitchen-sink potential from new CEO is real but has limits. The $0.77-$0.83 range is already conservative (10-14% decline). If management sandbagged by $0.02-$0.05, that would put actual at $0.82-$0.88 — with the high end exceeding $0.83. This is plausible if bioprocessing backlog converts and cost savings accelerate. I give 33%, reflecting the narrow path.